Patents by Inventor Vangipuram Rangan

Vangipuram Rangan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9994633
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 12, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
  • Publication number: 20150104866
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David B. PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU
  • Patent number: 8945546
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: February 3, 2015
    Assignee: Medarex, L.L.C.
    Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
  • Publication number: 20120230998
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 23, 2012
    Publication date: September 13, 2012
    Applicant: MEDAREX, INC.
    Inventors: Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU
  • Patent number: 8258266
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: September 4, 2012
    Assignee: Medarex, Inc.
    Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
  • Publication number: 20100077497
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 27, 2009
    Publication date: March 25, 2010
    Applicant: MEDAREX, INC.
    Inventors: Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU
  • Publication number: 20050191293
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 10, 2004
    Publication date: September 1, 2005
    Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine Cardarelli, Changyu Wang, David Passmore, Vangipuram Rangan, Thomas Lane, Hans Keirstead, Michael Liu